Symbols / BCLI $0.80 +0.00% Brainstorm Cell Therapeutics Inc.

Healthcare • Biotechnology • United States • OQB
BCLI Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Chaim Lebovits
Exch · Country OQB · United States
Market Cap 8.83M
Enterprise Value 9.53M
Income -10.31M
Sales —
FCF (ttm) -3.21M
Book/sh -0.91
Cash/sh 0.00
Employees 20
Insider 10d —
IPO Oct 07, 2003
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.93
PEG —
P/S —
P/B -0.88
P/C —
EV/EBITDA -0.98
EV/Sales —
Quick Ratio 0.01
Current Ratio 0.03
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.85
EPS next Y -0.86
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-05-15
ROA -4.36%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 11.03M
Shs Float 9.97M
Insider Own 10.27%
Instit Own 0.00%
Short Float 6.46%
Short Ratio 1.27
Short Interest 604.46K
52W High 1.33
vs 52W High -39.85%
52W Low 0.46
vs 52W Low 73.91%
Beta 0.28
Impl. Vol. —
Rel Volume 0.13
Avg Volume 13.29K
Volume 1.70K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.80
Price $0.80
Change 0.00%
About

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.80
Latest analyst target
3. DCF / Fair value
$-5.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.80
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-07-11 up Maxim Group Hold → Buy $2
2023-09-28 down Maxim Group Buy → Hold —
2023-03-31 main Maxim Group — → Buy $10
2021-02-05 up Maxim Group Hold → Buy —
2018-05-15 init HC Wainwright & Co. — → Buy $11
2017-08-17 main Maxim Group — → Buy $9
News
RSS: Latest BCLI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-26 LEBOVITS CHAIM Chief Executive Officer — 1,800,000 $0.00 $0
2026-02-26 YABLONKA URI Officer and Director — 150,000 $0.00 $0
2026-02-26 PATLIS ALLA Chief Financial Officer — 100,000 $0.00 $0
2026-02-26 FRENKEL JACOB A. Director — 200,000 $0.00 $0
2026-02-26 ARBEL IRIT Director — 120,000 $0.00 $0
2024-12-31 LEBOVITS CHAIM Chief Executive Officer — 120,000 $0.00 $0
2024-12-31 YABLONKA URI Officer and Director — 60,000 $0.00 $0
2024-12-31 PATLIS ALLA Chief Financial Officer — 40,000 $0.00 $0
2024-12-31 POLVERINO ANTHONY J Director — 24,000 $0.00 $0
2024-12-31 LINDBORG STACY R Director — 20,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
9.95
-14.88%
11.69
-45.46%
21.44
-13.63%
24.82
Research And Development
4.17
-10.23%
4.65
-56.72%
10.75
-23.00%
13.96
Selling General And Administration
5.78
-17.95%
7.04
-34.14%
10.69
-1.59%
10.87
General And Administrative Expense
5.78
-17.95%
7.04
-34.14%
10.69
-1.59%
10.87
Other Gand A
5.78
-17.95%
7.04
-34.14%
10.69
-1.59%
10.87
Total Expenses
9.95
-14.88%
11.69
-45.46%
21.44
-13.63%
24.82
Operating Income
-9.95
+14.88%
-11.69
+45.46%
-21.44
+13.63%
-24.82
Total Operating Income As Reported
-9.95
+14.88%
-11.69
+45.46%
-21.44
+13.63%
-24.82
EBITDA
-9.75
+14.83%
-11.45
+45.91%
-21.17
+13.71%
-24.54
Normalized EBITDA
-9.93
+14.37%
-11.60
+55.16%
-25.87
-5.42%
-24.54
Reconciled Depreciation
0.20
-17.08%
0.24
-9.43%
0.27
-7.02%
0.28
EBIT
-9.95
+14.88%
-11.69
+45.46%
-21.44
+13.63%
-24.82
Total Unusual Items
0.18
+21.77%
0.15
-96.87%
4.69
—
Total Unusual Items Excluding Goodwill
0.18
+21.77%
0.15
-96.87%
4.69
—
Net Income
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Pretax Income
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Net Non Operating Interest Income Expense
-0.53
-592.21%
-0.08
+82.77%
-0.45
-182.02%
0.55
Net Interest Income
-0.53
-592.21%
-0.08
+82.77%
-0.45
-182.02%
0.55
Interest Income Non Operating
—
—
—
0.55
Interest Income
—
—
—
0.55
Other Income Expense
0.18
+21.77%
0.15
-96.87%
4.69
—
Gain On Sale Of Security
0.18
+21.77%
0.15
-96.87%
4.69
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Net Income From Continuing Operation Net Minority Interest
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Net Income From Continuing And Discontinued Operation
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Net Income Continuous Operations
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Normalized Income
-10.49
+10.91%
-11.77
+46.22%
-21.89
+9.85%
-24.28
Net Income Common Stockholders
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Diluted EPS
-1.11
+51.95%
-2.31
+61.50%
-6.00
+39.39%
-9.90
Basic EPS
-1.11
+51.95%
-2.31
+61.50%
-6.00
+39.39%
-9.90
Basic Average Shares
9.27
+84.57%
5.02
+74.87%
2.87
+17.99%
2.43
Diluted Average Shares
9.27
+84.57%
5.02
+74.87%
2.87
+17.99%
2.43
Diluted NI Availto Com Stockholders
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Total Other Finance Cost
0.53
+592.21%
0.08
-82.77%
0.45
+182.02%
-0.55
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1.02
-44.21%
1.83
-56.46%
4.21
-50.21%
8.45
Current Assets
0.31
-20.26%
0.39
-79.73%
1.90
-38.86%
3.11
Cash Cash Equivalents And Short Term Investments
0.03
-84.49%
0.19
-85.62%
1.30
-56.42%
2.98
Cash And Cash Equivalents
0.03
-84.49%
0.19
-85.62%
1.30
+68.39%
0.77
Other Short Term Investments
—
—
0.00
-100.00%
2.21
Receivables
0.09
+36.51%
0.06
+23.53%
0.05
-43.96%
0.09
Other Receivables
0.09
+36.51%
0.06
+23.53%
0.05
-43.96%
0.09
Prepaid Assets
—
—
—
—
Other Current Assets
0.19
+42.22%
0.14
-75.36%
0.55
+1612.50%
0.03
Total Non Current Assets
0.71
-50.59%
1.45
-37.33%
2.31
-56.80%
5.34
Net PPE
0.44
-64.30%
1.24
-40.96%
2.10
-60.50%
5.32
Accumulated Depreciation
-3.20
-6.63%
-3.00
-8.69%
-2.76
-10.61%
-2.50
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.32
+0.00%
0.32
+0.00%
0.32
+0.93%
0.32
Other Properties
2.48
-19.43%
3.08
-16.77%
3.70
-44.40%
6.66
Leases
0.84
+0.00%
0.84
+0.00%
0.84
+0.00%
0.84
Non Current Prepaid Assets
—
—
0.02
-4.35%
0.02
Other Non Current Assets
0.27
+32.04%
0.21
-0.48%
0.21
+800.00%
0.02
Total Liabilities Net Minority Interest
11.01
+14.70%
9.60
+5.85%
9.07
-20.93%
11.47
Current Liabilities
11.01
+22.60%
8.98
+15.10%
7.80
-11.36%
8.80
Payables And Accrued Expenses
8.43
+20.45%
7.00
+13.00%
6.19
-1.81%
6.31
Payables
8.03
+25.92%
6.38
+28.78%
4.95
-20.40%
6.22
Accounts Payable
7.07
+16.23%
6.08
+22.73%
4.95
-20.40%
6.22
Current Accrued Expenses
0.40
-36.03%
0.62
-50.08%
1.24
+1376.19%
0.08
Pensionand Other Post Retirement Benefit Plans Current
2.37
+65.66%
1.43
+42.57%
1.00
-5.82%
1.06
Current Debt And Capital Lease Obligation
0.21
-62.11%
0.55
-8.96%
0.60
-57.74%
1.43
Current Capital Lease Obligation
0.21
-62.11%
0.55
-8.96%
0.60
-57.74%
1.43
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.62
-51.18%
1.27
-52.51%
2.67
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.17
-74.55%
0.67
-74.79%
2.67
Long Term Capital Lease Obligation
0.00
-100.00%
0.17
-74.55%
0.67
-74.79%
2.67
Stockholders Equity
-9.98
-28.61%
-7.76
-59.82%
-4.86
-61.13%
-3.02
Common Stock Equity
-9.98
-28.61%
-7.76
-59.82%
-4.86
-61.13%
-3.02
Capital Stock
0.02
+14.29%
0.01
+7.69%
0.01
+8.33%
0.01
Common Stock
0.02
+14.29%
0.01
+7.69%
0.01
+8.33%
0.01
Share Issued
11.04
+79.65%
6.14
+52.28%
4.03
+64.80%
2.45
Ordinary Shares Number
11.03
+79.67%
6.14
+52.30%
4.03
+64.85%
2.45
Treasury Shares Number
0.00
+0.00%
0.00
+0.06%
0.00
+0.00%
0.00
Additional Paid In Capital
227.06
+3.69%
218.97
+4.15%
210.26
+7.87%
194.91
Retained Earnings
-236.94
-4.55%
-226.64
-5.41%
-215.01
-8.69%
-197.82
Treasury Stock
0.12
+0.00%
0.12
+0.00%
0.12
+0.00%
0.12
Total Equity Gross Minority Interest
-9.98
-28.61%
-7.76
-59.82%
-4.86
-61.13%
-3.02
Total Capitalization
-9.98
-28.61%
-7.76
-59.82%
-4.86
-61.13%
-3.02
Working Capital
-10.70
-24.52%
-8.59
-45.62%
-5.90
-3.64%
-5.69
Invested Capital
-9.98
-28.61%
-7.76
-59.82%
-4.86
-61.13%
-3.02
Total Debt
0.21
-71.11%
0.72
-43.53%
1.27
-68.85%
4.09
Capital Lease Obligations
0.21
-71.11%
0.72
-43.53%
1.27
-68.85%
4.09
Net Tangible Assets
-9.98
-28.61%
-7.76
-59.82%
-4.86
-61.13%
-3.02
Tangible Book Value
-9.98
-28.61%
-7.76
-59.82%
-4.86
-61.13%
-3.02
Derivative Product Liabilities
0.00
-100.00%
0.45
-24.75%
0.59
0.00
Dueto Related Parties Current
0.97
+222.33%
0.30
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.97
+23.29%
-9.09
+55.55%
-20.46
-5.89%
-19.32
Cash Flow From Continuing Operating Activities
-6.97
+23.29%
-9.09
+55.55%
-20.46
-5.89%
-19.32
Net Income From Continuing Operations
-10.31
+11.32%
-11.62
+32.39%
-17.19
+29.18%
-24.28
Depreciation Amortization Depletion
0.20
-17.08%
0.24
-9.43%
0.27
-7.02%
0.28
Depreciation
0.20
-17.08%
0.24
-9.43%
0.27
-7.02%
0.28
Depreciation And Amortization
0.20
-17.08%
0.24
-9.43%
0.27
-7.02%
0.28
Stock Based Compensation
1.52
+102.67%
0.75
-49.66%
1.49
-11.41%
1.68
Operating Gains Losses
-0.18
-21.77%
-0.15
+96.75%
-4.53
—
Gain Loss On Investment Securities
-0.18
-21.77%
-0.15
+96.75%
-4.53
—
Change In Working Capital
1.79
+6.22%
1.69
+440.12%
-0.50
-116.59%
2.99
Change In Receivables
—
—
-0.47
-144.52%
1.07
Change In Prepaid Assets
-0.08
-120.70%
0.40
+184.42%
-0.47
—
Change In Payables And Accrued Expense
1.79
+45.13%
1.23
+800.00%
-0.18
-106.99%
2.52
Change In Accrued Expense
0.09
0.00
—
—
Change In Payable
1.70
+38.23%
1.23
+800.00%
-0.18
-106.99%
2.52
Change In Account Payable
0.99
-12.34%
1.13
+188.66%
-1.27
-150.32%
2.52
Change In Other Current Liabilities
0.09
+61.11%
0.05
-65.16%
0.15
+126.09%
-0.59
Investing Cash Flow
0.00
-100.00%
0.01
-99.45%
2.19
+119.74%
1.00
Cash Flow From Continuing Investing Activities
0.00
-100.00%
0.01
-99.45%
2.19
+119.74%
1.00
Net PPE Purchase And Sale
0.00
-100.00%
0.01
+166.67%
-0.02
+37.93%
-0.03
Purchase Of PPE
—
—
-0.02
+37.93%
-0.03
Sale Of PPE
0.00
-100.00%
0.01
—
—
Capital Expenditure
—
—
-0.02
+37.93%
-0.03
Net Investment Purchase And Sale
0.00
0.00
-100.00%
2.21
+115.29%
1.03
Financing Cash Flow
6.88
-13.64%
7.97
-58.02%
18.98
+7873.95%
0.24
Cash Flow From Continuing Financing Activities
6.88
-13.64%
7.97
-58.02%
18.98
+7873.95%
0.24
Net Issuance Payments Of Debt
0.58
0.00
—
—
Issuance Of Debt
0.58
0.00
—
—
Short Term Debt Issuance
0.58
0.00
—
—
Net Short Term Debt Issuance
0.58
0.00
—
—
Net Common Stock Issuance
4.35
-45.44%
7.97
-58.02%
18.98
+7873.95%
0.24
Common Stock Payments
—
—
—
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
1.50
0.00
—
0.00
Net Other Financing Charges
0.45
—
—
—
Changes In Cash
-0.10
+91.47%
-1.11
-256.24%
0.71
+103.94%
-18.08
Beginning Cash Position
0.37
-75.02%
1.49
+92.36%
0.77
-95.91%
18.86
End Cash Position
0.28
-25.61%
0.37
-75.02%
1.49
+92.36%
0.77
Free Cash Flow
-6.97
+23.29%
-9.09
+55.59%
-20.48
-5.82%
-19.35
Common Stock Issuance
4.35
-45.44%
7.97
-58.02%
18.98
+7873.95%
0.24
Issuance Of Capital Stock
4.35
-45.44%
7.97
-58.02%
18.98
+7873.95%
0.24
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category